

Wissenschaftliche Publikationen 2016

Originalarbeiten

Erstautorenschaften

Buschmann M, Seppenwoolde Y, Wiezorek T, Weibert K, Georg D.

Advanced optimization methods for whole pelvic and local prostate external beam therapy. Phys Med. 2016 Mar;32(3):465-73. doi: [10.1016/j.ejmp.2016.03.002](https://doi.org/10.1016/j.ejmp.2016.03.002)

Frings K, Gruber S, Kuess P, Kleiter M, Dörr W.

Modulation of radiation-induced oral mucositis by thalidomide : Preclinical studies. Strahlenther Onkol. 2016 Aug;192(8):561-8. doi: [10.1007/s00066-016-0989-5](https://doi.org/10.1007/s00066-016-0989-5)

Gruber S, Dörr W.

Tissue reactions to ionizing radiation-Oral mucosa. Mutat Res. 2016 Oct - Dec;770(Pt B):292-298. Review. doi [10.1016/j.mrrev.2016.07.007](https://doi.org/10.1016/j.mrrev.2016.07.007)

Jastaniyah N, Yoshida K, Tanderup K, Lindegaard JC, Sturdza A, Kirisits C, Šegedin B, Mahantshetty U, Rai B, Jürgenliemk-Schulz IM, Haie-Meder C, Banerjee S, Pötter R; EMBRACE Collaborative Group.

A volumetric analysis of GTV(D) and CTV(HR) as defined by the GEC ESTRO recommendations in FIGO stage IIB and IIIB cervical cancer patients treated with IGABT in a prospective multicentric trial (EMBRACE).

Radiother Oncol. 2016 Sep;120(3):404-411. doi: [10.1016/j.radonc.2016.05.029](https://doi.org/10.1016/j.radonc.2016.05.029)

Kirchheiner K, Nout RA, Lindegaard JC, Haie-Meder C, Mahantshetty U, Segedin B, Jürgenliemk-Schulz IM, Hoskin PJ, Rai B, Dörr W, Kirisits C, Bentzen SM, Pötter R, Tanderup K; EMBRACE Collaborative Group.

Dose-effect relationship and risk factors for vaginal stenosis after definitive radio(chemo)therapy with image-guided brachytherapy for locally advanced cervical cancer in the EMBRACE study.

Radiother Oncol. 2016 Jan;118(1):160-6. doi: [10.1016/j.radonc.2015.12.025](https://doi.org/10.1016/j.radonc.2015.12.025)

Kirchheiner K, Pötter R, Tanderup K, Lindegaard JC, Haie-Meder C, Petrič P, Mahantshetty U, Jürgenliemk-Schulz IM, Rai B, Cooper R, Dörr W, Nout RA; EMBRACE Collaborative Group.

Health-Related Quality of Life in Locally Advanced Cervical Cancer Patients After Definitive Chemoradiation Therapy Including Image Guided Adaptive Brachytherapy: An Analysis From the EMBRACE Study.

Int J Radiat Oncol Biol Phys. 2016 Apr 1;94(5):1088-98. doi: [10.1016/j.ijrobp.2015.12.363](https://doi.org/10.1016/j.ijrobp.2015.12.363)

Kirisits C, Schmid MP, Beriwal S, Pötter R.

In response to the letter to the editor from Sylvia van Dyk et al. regarding our editorial "High-tech image-guided therapy vs. low-tech, simple, cheap gynecologic brachytherapy".

Brachytherapy. 2016 Mar-Apr;15(2):207. doi: [10.1016/j.brachy.2015.12.006](https://doi.org/10.1016/j.brachy.2015.12.006)

Knäusl B, Fuchs H, Dieckmann K, Georg D.

Can particle beam therapy be improved using helium ions? - a planning study focusing on pediatric patients.

Acta Oncol. 2016 Jun;55(6):751-9. doi: [10.3109/0284186X.2015.1125016](https://doi.org/10.3109/0284186X.2015.1125016)

Kuess P, Georg D, Palmans H, Lechner W.

Technical Note: On the impact of the incident electron beam energy on the primary dose component of flattening filter free photon beams.

Med Phys. 2016 Aug;43(8):4507. doi: [10.1118/1.4954849](https://doi.org/10.1118/1.4954849)

Nesvacil N, Schmid MP, Pötter R, Kronreif G, Kirisits C.

Combining transrectal ultrasound and CT for image-guided adaptive brachytherapy of cervical cancer: Proof of concept.

Brachytherapy. 2016 Nov - Dec;15(6):839-844. doi: [10.1016/j.brachy.2016.08.009](https://doi.org/10.1016/j.brachy.2016.08.009)

Nesvacil N, Tanderup K, Lindegaard JC, **Pötter R**, **Kirisits C**.

Can reduction of uncertainties in cervix cancer brachytherapy potentially improve clinical outcome?
Radiother Oncol. 2016 Sep;120(3):390-396. doi: [10.1016/j.radonc.2016.06.008](https://doi.org/10.1016/j.radonc.2016.06.008)

Pötter R, Federico M, **Sturdza A**, Fotina I, Hegazy N, **Schmid M**, **Kirisits C**, **Nesvacil N**.

Value of Magnetic Resonance Imaging Without or With Applicator in Place for Target Definition in Cervix Cancer Brachytherapy.

Int J Radiat Oncol Biol Phys. 2016 Mar 1;94(3):588-97. doi: [10.1016/j.ijrobp.2015.09.023](https://doi.org/10.1016/j.ijrobp.2015.09.023)

Rumpold T, Schur S, Amering M, Ebert-Vogel A, Kirchheiner K, Masel E, Watzke H, Schrank B.

Hope as determinant for psychiatric morbidity in family caregivers of advanced cancer patients.

Psychooncology. 2017 May;26(5):672-678. doi: [10.1002/pon.4205](https://doi.org/10.1002/pon.4205)

Rumpold T, Schur S, Amering M, **Kirchheiner K**, Masel EK, Watzke H, Schrank B.

Informal caregivers of advanced-stage cancer patients: Every second is at risk for psychiatric morbidity.

Support Care Cancer. 2016 May;24(5):1975-1982. doi: [10.1007/s00520-015-2987-z](https://doi.org/10.1007/s00520-015-2987-z)

Schmid MP, **Nesvacil N**, **Pötter R**, Kronreif G, **Kirisits C**.

Transrectal ultrasound for image-guided adaptive brachytherapy in cervix cancer – An alternative to MRI for target definition?

Radiother Oncol. 2016 Sep;120(3):467-472. doi: [10.1016/j.radonc.2016.01.021](https://doi.org/10.1016/j.radonc.2016.01.021)

Selzer E, Grah A, Heiduschka G, Kornek G, Thurnher D.

Pre-therapeutic fibrinogen levels are of prognostic significance in locally advanced head and neck cancer.

Wien Klin Wochenschr. 2016 May;128(9-10):320-8. doi: [10.1007/s00508-016-0963-3](https://doi.org/10.1007/s00508-016-0963-3)

Seppenwoolde Y, Stock M, **Buschmann M**, **Georg D**, **Bauer-Novotny KY**, **Pötter R**, **Georg P**.

Impact of organ shape variations on margin concepts for cervix cancer ART.

Radiother Oncol. 2016 Sep;120(3):526-531. doi: [10.1016/j.radonc.2016.08.004](https://doi.org/10.1016/j.radonc.2016.08.004)

Sturdza A, **Pötter R**, Fokdal LU, Haie-Meder C, Tan LT, Mazon R, Petric P, Šegedin B, Jurgentliemk-Schulz IM, Nomden C, Gillham C, McArdle O, Van Limbergen E, Janssen H, Hoskin P, Lowe G, Tharavichitkul E, Villafranca E, Mahantshetty U, Georg P, **Kirchheiner K**, **Kirisits C**, Tanderup K, Lindegaard JC.

Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study.

Radiother Oncol. 2016 Sep;120(3):428-433. doi: [10.1016/j.radonc.2016.03.011](https://doi.org/10.1016/j.radonc.2016.03.011)

Westerveld H, de Leeuw A, **Kirchheiner K**, Dankulchai P, Oosterveld B, Oinam A, Hudej R,

Swamidas J, Lindegaard J, Tanderup K, **Pötter R**, **Kirisits C**; EMBRACE Collaborative Group.

Multicentre evaluation of a novel vaginal dose reporting method in 153 cervical cancer patients.

Radiother Oncol. 2016 Sep;120(3):420-427. doi: [10.1016/j.radonc.2016.05.002](https://doi.org/10.1016/j.radonc.2016.05.002)

Korrespondenzautorenschaften

Eder-Czembirek C, Czembirek C, Selzer E.

Neoadjuvant radiotherapy plus radical surgery for locally advanced stage III/IV oral cancer: Analysis of prognostic factors affecting overall survival.

Oral Oncol. 2016 Sep;60:1-7. doi: [10.1016/j.oraloncology.2016.06.014](https://doi.org/10.1016/j.oraloncology.2016.06.014)

Erratum in: Oral Oncol.2016 Dec;63:e8.

Eder-Czembirek C, Czembirek C, **Selzer E**.

Erratum to "Neoadjuvant radiotherapy plus radical surgery for locally advanced stage III/IV oral cancer: Analysis of prognostic factors affecting overall survival"

Oral Oncol. 60 (2016) 1-7. : doi: [10.1016/j.oraloncology.2016.10.016](https://doi.org/10.1016/j.oraloncology.2016.10.016)

Hofbauer J, **Kirisits C**, **Resch A**, Xu Y, **Sturdza A**, **Pötter R**, **Nesvacil N**.
Impact of heterogeneity-corrected dose calculation using a grid-based Boltzmann solver on breast and cervix cancer brachytherapy.
J Contemp Brachytherapy. 2016 Apr;8(2):143-9. doi: [10.5114/jcb.2016.59352](https://doi.org/10.5114/jcb.2016.59352)

Izewska J, Wesolowska P, Azangwe G, Followill DS, Thwaites DI, Arib M, Stefanic A, Viegas C, Suming L, Ekendahl D, Bulski W, **Georg D**.
Testing the methodology for dosimetry audit of heterogeneity corrections and small MLC-shaped fields: Results of IAEA multi-center studies.
Acta Oncol. 2016 Jul;55(7):909-16. doi: [10.3109/0284186X.2016.1139180](https://doi.org/10.3109/0284186X.2016.1139180)

Tanderup K, Lindegaard JC, **Kirisits C**, Haie-Meder C, **Kirchheiner K**, de Leeuw A, Jürgenliemk-Schulz I, Van Limbergen E, **Pötter R**.
Image Guided Adaptive Brachytherapy in cervix cancer: A new paradigm changing clinical practice and outcome.
Radiother Oncol. 2016 Sep;120(3):365-369. Editorial. doi: [10.1016/j.radonc.2016.08.007](https://doi.org/10.1016/j.radonc.2016.08.007)

Koautorenschaften

Ahmed MA, **Selzer E**, **Dörr W**, Jomrich G, Harpain F, Silberhumer GR, Müllauer L, Holzmann K, Grasl-Kraupp B, Grusch M, Berger W, Marian B.
Fibroblast growth factor receptor 4 induced resistance to radiation therapy in colorectal cancer.
Oncotarget. 2016 Oct 25;7(43):69976-69990. doi: [10.18632/oncotarget.12099](https://doi.org/10.18632/oncotarget.12099)

Araki A, Chocholous M, Gojo J, Dorfer C, Czech T, Heinzl H, **Dieckmann K**, Ambros IM, Ambros PF, Slavc I, Haberler C.
Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma.
Acta Neuropathol Commun. 2016 Aug 22;4(1):88. doi: [10.1186/s40478-016-0349-9](https://doi.org/10.1186/s40478-016-0349-9)

Berghoff AS, Fuchs E, Ricken G, Mlecnik B, Bindea G, Spanberger T, Hackl M, Widhalm G, **Dieckmann K**, Prayer D, Bilocq A, Heinzl H, Zielinski C, Bartsch R, Birner P, Galon J, Preusser M.
Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases.
Oncoimmunology. 2015 Jun 9;5(1):e1057388. eCollection 2016. [https://doi-org.ez.srv.meduniwien.ac.at/10.1080/2162402X.2015.1057388](https://doi.org.ez.srv.meduniwien.ac.at/10.1080/2162402X.2015.1057388)

Berghoff AS, Ricken G, Wilhelm D, Rajky O, Widhalm G, **Dieckmann K**, Birner P, Bartsch R, Preusser M.
Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC).
J Neurooncol. 2016 Oct;130(1):19-29. doi: [10.1007/s11060-016-2216-8](https://doi.org/10.1007/s11060-016-2216-8)

Berghoff AS, Schur S, Füreder LM, Gatterbauer B, **Dieckmann K**, Widhalm G, Hainfellner J, Zielinski CC, Birner P, Bartsch R, Preusser M.
Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers.
ESMO Open. 2016 Mar 16;1(2):e000024. eCollection 2016. doi: [10.1136/esmooopen-2015-000024](https://doi.org/10.1136/esmooopen-2015-000024)

Blatt K, **Herrmann H**, Stefanzi G, Sperr WR, Valent P.
Evaluation of in vitro effects of various targeted drugs on plasma cells and putative neoplastic stem cells in patients with multiple myeloma.
Oncotarget. 2016 Oct 4;7(40):65627-65642. doi: [10.18632/oncotarget.11593](https://doi.org/10.18632/oncotarget.11593)

Bojic M, Worel N, Sperr WR, Schellongowski P, Wohlfarth P, Schwarzinger I, Mitterbauer-Hohendanner G, Fischer G, **Dieckmann KU**, Lamm W, Leiner M, Schulenburg A, Mitterbauer M, Greinix HT, Kalhs P, Rabitsch W.
Umbilical Cord Blood Transplantation Is a Feasible Rescue Therapeutic Option for Patients Suffering from Graft Failure after Previous Hematopoietic Stem Cell Transplantation.
Oncology. 2016;90(3):160-6. doi: [10.1159/000443767](https://doi.org/10.1159/000443767)

Culen M, Borsky M, Nemethova V, Razga F, Smejkal J, Jurcek T, Dvorakova D, Zackova D, Weinbergerova B, Semerad L, Sadovnik I, Eisenwort G, **Herrmann H**, Valent P, Mayer J, Racil Z. Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects. *Oncotarget*. 2016 May 31;7(22):33016-24. doi: [10.18632/oncotarget.9108](https://doi.org/10.18632/oncotarget.9108)

De Puysseleir A, Lechner W, De Neve W, **Georg D**, De Wagter C. Absorbed dose measurements in the build-up region of flattened versus unflattened megavoltage photon beams. *Z Med Phys*. 2016 Jun;26(2):177-83. doi: [10.1016/j.zemedi.2016.02.005](https://doi.org/10.1016/j.zemedi.2016.02.005)

Fichtenbaum A, **Schmid R**, Mitulović G. Direct injection of HILIC fractions on the reversed-phase trap column improves protein identification rates for salivary proteins. *Electrophoresis*. 2016 Nov;37(22):2922-2929. doi: [10.1002/elps.201600222](https://doi.org/10.1002/elps.201600222)

Fiorino C, Broggi S, Fossati N, Cozzarini C, **Goldner G**, Wiegel T, Hinkelbein W, Karnes RJ, Boorjian SA, Haustermans K, Joniau S, Palorini F, Shariat S, Montorsi F, Van Poppel H, Di Muzio N, Calandrino R, Briganti A. Predicting the 5-Year Risk of Biochemical Relapse After Postprostatectomy Radiation Therapy in \geq PT2, pN0 Patients With a Comprehensive Tumor Control Probability Model. *Int J Radiat Oncol Biol Phys*. 2016 Oct 1;96(2):333-40. doi: [10.1016/j.ijrobp.2016.06.014](https://doi.org/10.1016/j.ijrobp.2016.06.014)

Fokdal L, **Sturdza A**, Mazon R, Haie-Meder C, Tan LT, Gillham C, Šegedin B, Jürgenliemk-Schultz I, **Kirisits C**, Hoskin P, Pötter R, Lindegaard JC, Tanderup K. Image guided adaptive brachytherapy with combined intracavitary and interstitial technique improves the therapeutic ratio in locally advanced cervical cancer: Analysis from the retroEMBRACE study. *Radiother Oncol*. 2016 Sep;120(3):434-440. doi: [10.1016/j.radonc.2016.03.020](https://doi.org/10.1016/j.radonc.2016.03.020)

Fossati N, Karnes RJ, Cozzarini C, Fiorino C, Gandaglia G, Joniau S, Boorjian SA, **Goldner G**, Hinkelbein W, Haustermans K, Tombal B, Shariat S, Karakiewicz PI, Montorsi F, Van Poppel H, Wiegel T, Briganti A. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy. *Eur Urol*. 2016 Apr;69(4):728-33. doi: [10.1016/j.eururo.2015.10.009](https://doi.org/10.1016/j.eururo.2015.10.009)

Frischer JM, Fraller A, Mallouhi A, Vogl UM, **Baier F**, Ertl A, Preusser M, Knosp E, Kitz K, Gatterbauer B. Evaluation of Dose-Staged Gamma Knife Radiosurgical Treatment Method for High-Risk Brain Metastases. *World Neurosurg*. 2016 Oct;94:352-359. doi: [10.1016/j.wneu.2016.07.038](https://doi.org/10.1016/j.wneu.2016.07.038)

Frischer JM, Marosi C, Woehrer A, Hainfellner JA, **Dieckmann KU**, Eiter H, Wang WT, Mallouhi A, Ertl A, Knosp E, Filipits M, Kitz K, Gatterbauer B. Gamma Knife Radiosurgery in Recurrent Glioblastoma. *Stereotact Funct Neurosurg*. 2016;94(4):265-272. doi: [10.1159/000448924](https://doi.org/10.1159/000448924)

Georg P, **Andrzejewski P**, Pinker K, **Georg D**. Erratum to: Treatment planning with functional MRI. *Radiologe*. 2016 Jan;56(1):47-8. doi: [10.1007/s00117-015-0054-x](https://doi.org/10.1007/s00117-015-0054-x)

Guckenberger M, Klement RJ, Allgäuer M, Andratschke N, Blanck O, Boda-Heggemann J, **Dieckmann K**, Duma M, Ernst I, Ganswindt U, Hass P, Henkenberens C, Holy R, Imhoff D, Kahl HK, Krempien R, Lohaus F, Nestle U, Nevinny-Stickel M, Petersen C, Semrau S, Streblow J, Wendt TG, Wittig A, Flentje M, Sterzing F. Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy. *Radiother Oncol*. 2016 Mar;118(3):485-91. doi: [10.1016/j.radonc.2015.09.008](https://doi.org/10.1016/j.radonc.2015.09.008)

Hoda MA, Klikovits T, Arns M, **Dieckmann K**, Zöchbauer-Müller S, Geltner C, Baumgartner B, Errhalt P, Machan B, Pohl W, Hutter J, Eckmayr J, Studnicka M, Flicker M, Cerkl P, Klepetko W. Management of malignant pleural mesothelioma-part 2: therapeutic approaches : Consensus of the Austrian Mesothelioma Interest Group (AMIG). Wien Klin Wochenschr. 2016 Sep;128(17-18):618-26. doi: [10.1007/s00508-016-1036-3](https://doi.org/10.1007/s00508-016-1036-3)

Kadletz L, Bigenzahn J, Thurnher D, Stanisz I, Erovic BM, Schneider S, **Schmid R**, Seemann R, Birner P, Heiduschka G. Evaluation of Polo-like kinase 1 as a potential therapeutic target in Merkel cell carcinoma. Head Neck. 2016 Apr;38 Suppl 1:E1918-25. doi: [10.1002/hed.24349](https://doi.org/10.1002/hed.24349)

Klement RJ, Allgäuer M, Andratschke N, Blanck O, Boda-Heggemann J, **Dieckmann K**, Duma M, Ernst I, Flentje M, Ganswindt U, Hass P, Henkenberens C, Imhoff D, Kahl HK, Krempien R, Lohaus F, Nestle U, Nevinny-Stickel M, Petersen C, Schmitt V, Semrau S, Sterzing F, Streblov J, Wendt TG, Wittig A, Guckenberger M. Bayesian Cure Rate Modeling of Local Tumor Control: Evaluation in Stereotactic Body Radiation Therapy for Pulmonary Metastases. Int J Radiat Oncol Biol Phys. 2016 Mar 15;94(4):841-9. doi: [10.1016/j.ijrobp.2015.12.004](https://doi.org/10.1016/j.ijrobp.2015.12.004)

Kortmann RD, Freeman C, Marcus K, Claude L, **Dieckmann K**, Halperin E, Esiashvili N, Paulino A, Mahajan A, Seiersen K, Ahern V, Ricardi U, Carrie C. Paediatric radiation oncology in the care of childhood cancer: A position paper by the International Paediatric Radiation Oncology Society (PROS). Radiother Oncol. 2016 May;119(2):357-60. Review. doi: [10.1016/j.radonc.2016.03.009](https://doi.org/10.1016/j.radonc.2016.03.009)

Mazon R, Fokdal LU, **Kirchheiner K**, Georg P, Jastaniyah N, Šegedin B, Mahantshetty U, Hoskin P, Jürgenliemk-Schulz I, **Kirisits C**, Lindegaard JC, **Dörr W**, Haie-Meder C, Tanderup K, **Pötter R**; EMBRACE collaborative group. Dose-volume effect relationships for late rectal morbidity in patients treated with chemoradiation and MRI-guided adaptive brachytherapy for locally advanced cervical cancer: Results from the prospective multicenter EMBRACE study. Radiother Oncol. 2016 Sep;120(3):412-419. doi: [10.1016/j.radonc.2016.06.006](https://doi.org/10.1016/j.radonc.2016.06.006)

Mohamed S, Lindegaard JC, de Leeuw AA, Jürgenliemk-Schulz I, **Kirchheiner K**, **Kirisits C**, **Pötter R**, Tanderup K. Vaginal dose de-escalation in image guided adaptive brachytherapy for locally advanced cervical cancer. Radiother Oncol. 2016 Sep;120(3):480-485. doi: [10.1016/j.radonc.2016.05.020](https://doi.org/10.1016/j.radonc.2016.05.020)

Ott OJ, Strnad V, Hildebrandt G, **Kauer-Dorner D**, Knauerhase H, Major T, Łyczek J, Guinot JL, Dunst J, Miguelez CG, Slampa P, Allgäuer M, Lössl K, Polat B, Kovács G, Fishedick AR, Wendt TG, Fietkau R, Kortmann RD, **Resch A**, Kulik A, Arribas L, Niehoff P, Guedea F, Schlamann A, **Pötter R**, Gall C, Malzer M, Uter W, Polgár C; Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: Accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: Early toxicity and patient compliance. Radiother Oncol. 2016 Jul;120(1):119-23. doi: [10.1016/j.radonc.2016.06.019](https://doi.org/10.1016/j.radonc.2016.06.019)

Petric P, **Kirisits C**. Potential role of TRAns Cervical Endosonography (TRACE) in brachytherapy of cervical cancer: proof of concept. J Contemp Brachytherapy. 2016 Jun;8(3):215-20. doi: [10.5114/jcb.2016.60502](https://doi.org/10.5114/jcb.2016.60502)

Pinker K, Andrzejewski P, Baltzer P, Polanec SH, **Sturdza A**, **Georg D**, Helbich TH, Karanikas G, Grimm C, Polterauer S, **Poetter R**, Wadsak W, Mitterhauser M, Georg P. Multiparametric [18F]Fluorodeoxyglucose/ [18F]Fluoromisonidazole Positron Emission Tomography/ Magnetic Resonance Imaging of Locally Advanced Cervical Cancer for the Non-Invasive Detection of Tumor Heterogeneity: A Pilot Study. PLoS One. 2016 May 11;11(5):e0155333. doi: [10.1371/journal.pone.0155333](https://doi.org/10.1371/journal.pone.0155333)

Polanec S, Helbich TH, Bickel H, Pinker-Domenig K, **Georg D**, Shariat SF, Aulitzky W, Susani M, Baltzer PA.

Head-to-head comparison of PI-RADS v2 and PI-RADS v1.

Eur J Radiol. 2016 Jun;85(6):1125-31. doi: [10.1016/j.ejrad.2016.03.025](https://doi.org/10.1016/j.ejrad.2016.03.025)

Polanec SH, Pinker-Domenig K, Brader P, **Georg D**, Shariat S, Spick C, Susani M, Helbich TH, Baltzer PA.

Multiparametric MRI of the prostate at 3 T: limited value of 3D (1)H-MR spectroscopy as a fourth parameter.

World J Urol. 2016 May;34(5):649-56. doi: [10.1007/s00345-015-1670-9](https://doi.org/10.1007/s00345-015-1670-9)

Sadovnik I, Hoelbl-Kovacic A, **Herrmann H**, Eisenwort G, Cerny-Reiterer S, Warsch W, Hoermann G, Greiner G, Blatt K, Peter B, Stefanzi G, Berger D, Bilban M, Herndlhofer S, Sill H, Sperr WR, Streubel B, Mannhalter C, Holyoake TL, Sexl V, Valent P.

Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML.

Clin Cancer Res. 2016 Apr 15;22(8):2051-61. doi: [10.1158/1078-0432.CCR-15-0767](https://doi.org/10.1158/1078-0432.CCR-15-0767)

Schneider S, Thurnher D, Kadletz L, Seemann R, Brunner M, Kotowski U, **Schmid R**, Lill C, Heiduschka G.

Effects of neratinib and combination with irradiation and chemotherapy in head and neck cancer cells.

Oral Dis. 2016 Nov;22(8):797-804. doi: [10.1111/odi.12552](https://doi.org/10.1111/odi.12552)

Schur S, Weixler D, Gabl C, Kreye G, Likar R, Masel EK, Mayrhofer M, Reiner F, Schmidmayr B, **Kirchheiner K**, Watzke HH; AUPACS (Austrian Palliative Care Study) Group.

Sedation at the end of life - a nation-wide study in palliative care units in Austria.

BMC Palliat Care. 2016 May 14;15:50. doi: [10.1186/s12904-016-0121-8](https://doi.org/10.1186/s12904-016-0121-8)

Siavashpour Z, Aghamiri MR, Jaber R, Dehghan-Manshadi HR, Sedaghat M, **Kirisits C**.

Evaluating the utility of "3D Slicer" as a fast and independent tool to assess intrafractional organ dose variations in gynecological brachytherapy.

Brachytherapy. 2016 Jul-Aug;15(4):514-23. doi: [10.1016/j.brachy.2016.03.009](https://doi.org/10.1016/j.brachy.2016.03.009)

Siavashpour Z, Aghamiri MR, Jaber R, ZareAkha N, Manshadi HR, **Kirisits C**, Sedaghat M.

A comparison of organs at risk doses in GYN intracavitary brachytherapy for different tandem lengths and bladder volumes.

J Appl Clin Med Phys. 2016 May;17(3):5-13. doi: [10.1120/jacmp.v17i3.5584](https://doi.org/10.1120/jacmp.v17i3.5584)

Siavashpour Z, Aghamiri MR, Jaber R, Manshadi HR, Ghaderi R, **Kirisits C**.

Optimum organ volume ranges for organs at risk dose in cervical cancer intracavitary brachytherapy.

J Contemp Brachytherapy. 2016 Apr;8(2):135-42. doi: [10.5114/jcb.2016.59687](https://doi.org/10.5114/jcb.2016.59687)

Strnad V, Ott OJ, Hildebrandt G, **Kauer-Dorner D**, Knauerhase H, Major T, Lyczek J, Guinot JL, Dunst J, Gutierrez Miguelez C, Slampa P, Allgäuer M, Lössl K, Polat B, Kovács G, Fishedick AR, Wendt TG, Fietkau R, Hindemith M, **Resch A**, Kulik A, Arribas L, Niehoff P, Guedea F, Schlamann A, **Pötter R**, Gall C, Malzer M, Uter W, Polgár C; Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO).

5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial.

Lancet. 2016 Jan 16;387(10015):229-38. doi: [10.1016/S0140-6736\(15\)00471-7](https://doi.org/10.1016/S0140-6736(15)00471-7)

Tamandl D, Ta J, **Schmid R**, Preusser M, Paireder M, Schoppmann SF, Haug A, Ba-Ssalamah A.

Prognostic value of volumetric PET parameters in unresectable and metastatic esophageal cancer.

Eur J Radiol. 2016 Mar;85(3):540-5. doi: [10.1016/j.ejrad.2016.01.002](https://doi.org/10.1016/j.ejrad.2016.01.002)

Tanderup K, Fokdal LU, **Sturdza A**, Haie-Meder C, Mazon R, van Limbergen E, Jürgenliemk-Schulz I, Petric P, Hoskin P, **Dörr W**, Bentzen SM, **Kirisits C**, Lindegaard JC, **Pötter R**.

Effect of tumor dose, volume and overall treatment time on local control after radiochemotherapy including MRI guided brachytherapy of locally advanced cervical cancer.

Radiother Oncol. 2016 Sep;120(3):441-446. doi: [10.1016/j.radonc.2016.05.014](https://doi.org/10.1016/j.radonc.2016.05.014)

Walsh S, Roelofs E, **Kuess P**, Lambin P, Jones B, **Georg D**, Verhaegen F.
A validated tumor control probability model based on a meta-analysis of low, intermediate, and high-risk prostate cancer patients treated by photon, proton, or carbon-ion radiotherapy.
Med Phys. 2016 Feb;43(2):734-47. doi: [10.1118/1.4939260](https://doi.org/10.1118/1.4939260)